share_log

SciSparc | CORRESP: CORRESP

SciSparc | CORRESP: CORRESP

SciSparc | CORRESP：信函
美股SEC公告 ·  2024/09/04 00:36

Moomoo AI 已提取核心訊息

SciSparc Ltd., a biopharmaceutical company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Tel Aviv, Israel, submitted the request on September 3, 2024, with the aim for the Registration Statement to become effective on September 5, 2024, at 4:15 p.m. Eastern Time. This acceleration would facilitate SciSparc's proposed public offering of securities as detailed in the Registration Statement. The company has acknowledged its understanding of the responsibilities under the Securities Act in relation to the public offering. SciSparc has also requested that the SEC confirm the effectiveness of the Registration Statement both by telephone and in writing.
SciSparc Ltd., a biopharmaceutical company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Tel Aviv, Israel, submitted the request on September 3, 2024, with the aim for the Registration Statement to become effective on September 5, 2024, at 4:15 p.m. Eastern Time. This acceleration would facilitate SciSparc's proposed public offering of securities as detailed in the Registration Statement. The company has acknowledged its understanding of the responsibilities under the Securities Act in relation to the public offering. SciSparc has also requested that the SEC confirm the effectiveness of the Registration Statement both by telephone and in writing.
生科斯帕克有限公司，一家生物製藥公司，已正式向美國證券交易委員會（SEC）提出請求，加快其F-1表格的註冊聲明的生效速度。總部位於以色列特拉維夫的這家公司於2024年9月3日提交了請求，目的是使註冊聲明在2024年9月5日美東時間下午4:15生效。這種加速將有助於生科斯帕克擬議中的證券公開發行，如註冊聲明中所述。公司已承認其對與公開發行相關的證券法責任的理解。生科斯帕克還要求SEC通過電話和書面形式確認註冊聲明的有效性。
生科斯帕克有限公司，一家生物製藥公司，已正式向美國證券交易委員會（SEC）提出請求，加快其F-1表格的註冊聲明的生效速度。總部位於以色列特拉維夫的這家公司於2024年9月3日提交了請求，目的是使註冊聲明在2024年9月5日美東時間下午4:15生效。這種加速將有助於生科斯帕克擬議中的證券公開發行，如註冊聲明中所述。公司已承認其對與公開發行相關的證券法責任的理解。生科斯帕克還要求SEC通過電話和書面形式確認註冊聲明的有效性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。